X
Xiaoxia Zuo
Researcher at Central South University
Publications - 34
Citations - 356
Xiaoxia Zuo is an academic researcher from Central South University. The author has contributed to research in topics: Medicine & Adalimumab. The author has an hindex of 8, co-authored 34 publications receiving 196 citations.
Papers
More filters
Journal ArticleDOI
PKM2-dependent glycolysis promotes skeletal muscle cell pyroptosis by activating the NLRP3 inflammasome in dermatomyositis/polymyositis
Di Liu,Yizhi Xiao,Bin Zhou,Gao Siming,Liya Li,Lijuan Zhao,Weilin Chen,Bingying Dai,Qiu-Xiang Li,Hui-Qian Duan,Xiaoxia Zuo,Hui Luo,Honglin Zhu +12 more
TL;DR: Upregulated glycolysis in the lesioned muscle tissues of DM/PM was revealed, which activated the NLRP3 inflammasome and leaded to pyroptosis in muscle cells.
Journal ArticleDOI
The effect of pulse methylprednisolone induction therapy in Chinese patients with dialysis-dependent MPO-ANCA associated vasculitis.
Li Huang,Yong Zhong,Joshua D. Ooi,Ya Ou Zhou,Xiaoxia Zuo,Hui Luo,Jinbiao Chen,Ting Wu,Yingqiang Yang,Ting Meng,Zhou Xiao,Wei Lin,Xiang Ao,Xiangcheng Xiao,Qiaoling Zhou,Ping Xiao +15 more
TL;DR: It is suggested that the addition of pulse MP to standard immunosuppressive induction therapy for remission appears to confer no benefit in terms of improving patient outcomes.
Journal ArticleDOI
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.
Jinmei Su,Jinmei Su,Mengtao Li,Mengtao Li,Lan He,Dongbao Zhao,Weiguo Wan,Yi Liu,Jianhua Xu,Jian Xu,Huaxiang Liu,Lindi Jiang,Huaxiang Wu,Xiaoxia Zuo,Cibo Huang,Xiumei Liu,Fen Li,Zhiyi Zhang,Xiangyuan Liu,Lingli Dong,Tianwang Li,Haiying Chen,Jingyang Li,Dongyi He,Xin Lu,Anbin Huang,Yi Tao,Yanyan Wang,Zhuoli Zhang,Wei Wei,Xiaofeng Li,Xiaofeng Zeng,Xiaofeng Zeng +32 more
TL;DR: HS016 resembled adalimumab in efficacy and safety over the 24-week treatment period, and the rates of treatment-emergent adverse events were not significantly different between the two groups, with most TEAEs being mild to moderate.
Journal ArticleDOI
Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.
Yuan An,Yunshan Zhou,Liqi Bi,Bo Liu,Hong Wang,Jin Lin,Danyi Xu,Mei Wang,Jing Zhang,Yongfu Wang,Yan An,Ping Zhu,Ronghua Xie,Zhiyi Zhang,Yifang Mei,Xiangyuan Liu,Xiaoli Deng,Zhong-qiang Yao,Zhuoli Zhang,Yu Wang,Weiguo Xiao,Hui Shen,Xiuyan Yang,Hanshi Xu,Feng Yu,Guochun Wang,Xin Lu,Yang Li,Yingnan Li,Xiaoxia Zuo,Yisha Li,Yi Liu,Yi Zhao,Jianping Guo,Lingyun Sun,Ming-Hui Zhao,Zhanguo Li +36 more
TL;DR: Treatment with a combined immunosuppressive agent is superior to routine CYC only therapy in lupus nephritis.
Journal ArticleDOI
Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study.
Yanwei Lin,Xiao-Xiang Chen,Huihua Ding,Ping Ye,Jieruo Gu,Xiaoxia Wang,Zhenyu Jiang,Detian Li,Zhongming Wang,Wubin Long,Zhijun Li,Gengru Jiang,Xiao-Mei Li,Liqi Bi,Lindi Jiang,Jian Wu,Lian Guo,Xiaoyan Cai,Xin Lu,Qinkai Chen,Hong Chen,Ai Peng,Xiaoxia Zuo,Rui Ning,Zhe Zhang,Yanfei Tai,Tao Zhang,Chunde Bao +27 more
TL;DR: In this article, the authors evaluated the efficacy and safety of SHR4640, a highly selective urate transporter 1 inhibitor, in Chinese subjects with hyperuricaemia, and reported a superior sUA-lowering effect and well tolerated safety profile after 5-week treatment with once-daily 5´mg/10´mg SHR 4640 as compared with placebo in Chinese patients with hyperuria.